Back to today’s briefing

Story perspectives

MBX Biosciences Shares Surge on Promising Canvuparatide Data

9/22/2025

42 7

Summary

Story summary

MBX Biosciences shares rose to a nine-month high after canvuparatide data for chronic hypoparathyroidism.
Canvuparatide produced a 63% response in 12 weeks, with 79% in an open-label extension.
Urine calcium fell 48% versus 33% placebo; side effects were mild, with 19% injection-site pain.
Phase 3 planned for 2026; analysts say efficacy lags Yorvipath; market may reach $1.32B by 2032.

1 of 1

Story summary

MBX Biosciences shares rose to a nine-month high after canvuparatide data for chronic hypoparathyroidism.
Canvuparatide produced a 63% response in 12 weeks, with 79% in an open-label extension.
Urine calcium fell 48% versus 33% placebo; side effects were mild, with 19% injection-site pain.
Phase 3 planned for 2026; analysts say efficacy lags Yorvipath; market may reach $1.32B by 2032.